The 11-14 week scan

Bailliere's Best Practice and Research in Clinical Obstetrics and Gynaecology

Volumn 14, Issue 4, 2000, Pages 581-594

  Nicolaides, Kypros H ^a   Heath, Victoria ^a   Liao, Adolfo W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chromosomal defects; Fetal abnormalities; Free human chorionic gonadotrophin; Nuchal translucency; Pregnancy associated plasma protein A; Screening; Ultrasonography

Indexed keywords

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PROTEIN A;

BONE DYSPLASIA; CHROMOSOME ABERRATION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FETUS; FETUS DISEASE; GENETIC DISORDER; HEART DISEASE; HUMAN; MATERNAL AGE; MULTIPLE PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; STAFF TRAINING; TRISOMY 21; ULTRASOUND;

EID: 0033801180     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2000.0098     Document Type: Article

References (65)

1. Diagnosis of fetal abnormalities at the 10-14 week scan
2. Maternal age and gestation-specific risk for trisomy 21
3. Maternal age and gestational age-specific risks for chromosomal defects
4. New estimates of Down syndrome risks at chorionic villus sampling, amniocentesis, and livebirth in women of advanced maternal age from a uniquely defined population
5. Fetal loss in Down syndrome pregnancies
6. Nuchal translucency and chromosomal defects
7. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
8. Nuchal translucency measurement: Training of potential examiners
9. The effect of nuchal cord on nuchal translucency measurement at 10-14 weeks
10. First trimester nuchal translucency screening of the general population: Data from three centres
11. First trimester fetal nuchal translucency: Problems with screening the general population I
12. Results of measurement of fetal nuchal translucency before and after training
13. First-trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age
14. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units
15. First trimester fetal nuchal translucency: Problems with screening the general population. II
16. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice
17. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities
18. Comparison between two methods of standardization for gestational age differences in fetal nuchal translucency measurement in first-trimester screening for trisomy 21
19. Increased nuchal translucency as a marker for fetal chromosomal defects
20. Results of routine fetal nuchal translucency measurement at 10-13 weeks in 4233 unselected pregnant women
21. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population
22. First trimester sonographic detection of chromosomal abnormalities in an unselected population
23. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome
24. Evaluation of first-trimester screening by fetal nuchal translucency and maternal age
25. Prenatal diagnosis of trisomy 18 at the 10-14 week ultrasound scan
26. Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation
27. Detection of sex chromosome abnormalities by nuchal translucency screening at 10-14 weeks
28. Early prenatal diagnosis of triploidy
29. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
30. Single uterine entry for genetic amniocentesis in twin pregnancies
31. Efficacy of second-trimester selective termination for fetal abnormalities: International collaborative experience among the world's largest centers
32. First-trimester prenatal diagnosis in twin pregnancies
33. Genetic analysis prior to selective fetal reduction in multiple pregnancies: Technical aspects and clinical outcome
34. Fetal karyotyping in twin pregnancies: Selection of technique by measurement of fetal nuchal translucency
35. Management of twin pregnancies with fetal trisomies
36. Maternal serum pregnancy associated placental protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy
37. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free-human chorionic gonadotropin and pregnancy-associated plasma protein-A
38. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy
39. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters
40. Prenatal screening for Down's syndrome - A search for the family's values
41. The effect of nuchal translucency measurement on second trimester biochemical screening for Down's syndrome
42. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome
43. Ultrasonographically detectable markers of fetal chromosomal abnormalities
44. Assessment of risks
45. Fetal mild hydronephrosis and chromosomal defects: Relation to maternal age and gestation
46. Fetal choroid plexus cysts and trisomy 18: Assessment of risk based on ultrasound findings and maternal age
47. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation
48. Prenatal detection of heart defects at the routine fetal examination at 18 weeks in a non-selected population
49. Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses
50. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects
51. First-trimester diagnosis of fetal congenital heart disease by transvaginal two-dimensional and Doppler echocardiography
52. Early diagnosis of fetal congenital heart disease by transvaginal echocardiography
53. Prenatal diagnosis of ventricular septal defect and overriding aorta at 14 weeks' gestation, using transvaginal sonography
54. First-trimester diagnosis of fetal congenital heart disease by transvaginal ultrasonography
55. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population based cohort study
56. Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency
57. First trimester transabdominal fetal echocardiography
58. Screening for chromosomal abnormalities at 11-14 weeks: The role of ductus venosus blood flow
59. Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses
60. Fetal nuchal translucency thickness at 10-14 weeks' gestation and congenital diaphragmatic hernia
61. Collagen type VI gene expression in the skin of trisomy 21 fetuses
62. Morphological classification of nuchal skin in fetuses with trisomy 21, 18 and 13 at 12-18 weeks and in a trisomy 16 mouse
63. Lymphatic vessel hypoplasia in fetuses with Turner syndrome
64. Increased fetal nuchal translucency thickness at 10-14 weeks: Is screening for maternal-fetal infection necessary?
65. Fetal hydrops secondary to human parvovirus infection in early pregnancy